home > PRODUCTS > DERMAL FILLER > Intraline
Intraline Two
Size: 1x1ml

£ 70.00

RRP: £87.50

OFF: 20%

SKU: D / K / 003

In stock




    Intraline One and Intraline Two are transparent, injectable implants in the form of a viscous, sterile, non-pyrogenic gel. Intraline One and Intraline Two are composed of cross-linked sodium hyaluronate of non-animal origin.

    Intraline One and Intraline Two are supplied in a graded, disposable, 1.0ml glass syringe. The product is for single use only. Two disposable sterile needles are provided with each syringe. Information about the needle size and sterilization method can be found on the outer package of the needle. The volume in each syringe is stated on the outer package. Two patient record labels will be included in each package to ensure product traceability.

    Intraline One is intended for treatment of moderate wrinkles and lip enhancement. The product should be injected intradermally through a needle into mid dermis.

    Intraline Two is intended for treatment of deep wrinkles and folds, and facial tissue augmentation. The product should be injected intradermally through a needle into the deep layer of the dermis and/or the surface layer of the subcutis.

    Warnings and Precautions:
    - Always observe the general precautions applicable to intradermal injections.
    - Intraline One and Intraline Two contain traces of BDDE (1,4-butanediol diglycidyl ether, less than 0.0001%) used as cross-linking agent, which in rare cases can cause irritation to the dermis.
    - Intraline One and Intraline Two may only be used as an intradermal implant by properly trained, qualified physicians or the authorized staff members in accordance with national legislation.
    - The customary intradermal injection technique must be used.
    - Ensure that the integrity of the syringe and needle has not been compromised and check the expiry date prior to use.
    - Do not mix Intraline One and Intraline Two with other products or inject the products into the blood stream.
    - Do not inject Intraline One and Intraline Two directly adjacent to a permanent implant or in connection with other on-going or planned skin treatments, e.g. laser treatment, in the same area.
    - Do not use Intraline One or Intraline Two on patients with infections or inflammations in the intended injection area.
    - Please notice that injections of Intraline One or Intraline Two can reactivate a latent herpes simplex virus or cause angioedematype swelling.
    - If using substances that may have an effect on the platelet function, such as anti-inflammatory drugs or aspirin, the patient may to a larger extent experience bruising or bleeding at injection sites.

    - Intraline One and Intraline Two have not been tested on pregnant or breast-feeding women or on children.

    - Intraline One and Intraline Two must not be administered to patients with any acute or chronic skin disease or inflammation (such as pimples, rashes or hives) within or close to the area selected for correction.

    - Intraline One and Intraline Two must not be administered to patients with bleeding disorders or in patients who are taking thrombolytics or anticoagulants.

    Patient Information:
    - After treatment with Intraline One and/or Intraline Two, undesirable short-term reactions may occur at the injection site, such as pain, tenderness, redness or swelling. The reactions normally appear shortly after treatment and may last up to 7 days for injections into the skin and up to 14 for injection into the lips. If the patient should experience the discomfort as severe or if the site gives rise to other conditions, such as oedema or prolonged swelling, contact the physician who administered the treatment.

    - Intraline One and Intraline Two break down naturally over time and are reabsorbed by the surrounding tissue. Durability varies with the patient and the site of the implant.

    - The patient must not expose the treated area to extreme temperatures (e.g. cold, heat, sun bathing, solarium etc.) during the first week after treatment or until any undesirable reactions have fully healed. Strenuous exercise should be avoided within the first day or two following application.
    - The patient should be informed not to apply make-up prior to, and up to at least 12 hours after, treatment.


Medicine Healthcare Regulatory Agency: Pharmaceutical Wholesale Distribution License No: UK WDA (H) 46138

We accept the following payment methods